Ligand Pharmaceuticals Inc.
3911 Sorrento Valley Boulevard
487 articles with Ligand Pharmaceuticals Inc.
Eric Ostertag, CEO of Poseida Therapeutics, believes the future of CAR-T programs is with allogeneic approaches and not autologous.
Ligand Pharmaceuticals Incorporated reported financial results for the three and nine months ended September 30, 2021 and provided an operating forecast and program updates.
Ligand Pharmaceuticals Incorporated announced it is pursuing plans to split Ligand into two separate, publicly traded companies with one featuring the OmniAb business, and the other featuring Ligand’s existing collection of core royalties and the technologies, pipeline and contracts associated with the Pelican protein expression platform and the Captisol business.
Ligand and CR Double-Crane Enter Collaboration Agreement to Develop an Oral COVID-19 Therapeutic Using Ligand’s BEPro Technology™
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced the signing of a collaboration agreement granting China Resources Double-Crane Pharmaceutical Co., Ltd. (CRDC) exclusive Asia territorial rights to develop a novel investigational oral COVID-19 antiviral therapeutic compound using Ligand’s BEPro technology.
Ligand’s Partner Gloria Biosciences Receives Approval in China for Zimberelimab for the Treatment of Recurrent or Refractory Classical Hodgkin’s Lymphoma
Ligand Pharmaceuticals Incorporated today announced that its partner Gloria Biosciences (GloriaBio) has received approval from China’s National Medical Products Administration (NMPA) for zimberelimab (GLS-010), an OmniAb-derived anti-PD-1 monoclonal antibody for the treatment of recurrent or refractory classical Hodgkin’s lymphoma (cHL).
Ligand Partner Travere Therapeutics Announces Positive Topline Interim Results from the Ongoing Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy
Ligand Pharmaceuticals Incorporated announces that its partner Travere Therapeutics, Inc. today announced positive topline interim results from the ongoing pivotal Phase 3 PROTECT Study of sparsentan, an investigational product candidate for the treatment of IgA nephropathy (IgAN).
Ligand Pharmaceuticals Incorporated reported financial results for the three and six months ended June 30, 2021 and provided an operating forecast and program updates.
Ligand Partner Jazz Pharmaceuticals Launches RYLAZE™ (asparaginase erwinia chrysanthemi (recombinant)-rywn), Formerly JZP458
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has launched Rylaze™
Ligand’s Partner Merck Receives FDA Approval for VAXNEUVANCE™ for the Prevention of Invasive Pneumococcal Disease in Adults Caused by 15 Serotypes
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its partner Merck has received approval from the U.S. Food and Drug Administration (FDA) for VAXNEUVANCE TM.
There are two PDUFA dates on the U.S. Food and Drug Administration’s calendar for this week. Here’s a look.
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will report financial results for the three and six months ended June 30, 2021 after the close of the U.S. financial markets on Thursday, July 29, 2021 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time.
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will report financial results for the three months ended March 31, 2021 after the close of the U.S. financial markets on Monday, May 3, 2021 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Speakers on the call will include Ligand’s CEO John Higgins, President and COO Matt Foehr and Executive Vice President and CFO Matt Korenberg.
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and 12 months ended December 31, 2020 and provided an operating forecast and program updates.
Ligand Partner Travere Therapeutics Announces Achievement of Interim Proteinuria Endpoint in the Ongoing Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
Sparsentan achieved statistically significant response on interim proteinuria endpoint compared to irbesartan after 36-weeks of treatment To date in the study, sparsentan has been generally well-tolerated and has shown a safety profile comparable to irbesartan
Ligand’s Fourth Quarter Financial Results to be Reported February 3 rd
Milestone payment triggered by acceptance for review of a BLA for V114, an investigational 15-valent pneumococcal conjugate vaccine that utilizes Ligand’s CRM197 carrier protein
iMetabolic Biopharma Corporation Announces Expansion of its Strategic OmniAb Antibody Discovery Partnership with Ligand Pharmaceuticals Accelerating iMetabolic’s iPlatform™ Technology and Pipeline Development
iMetabolic Biopharma Corporation (iMBP) announces expansion of its strategic partnership relationship with Ligand Pharmaceuticals, building on an earlier alliance agreement initiated in 2018, giving access to Ligand’s OmniAb platform. In this new agreement, iMBP gains access to additional OmniAb species and technologies, enabling the acceleration of iMBP’s development of assets through its iPlatform™ Technology. This stre
Ligand’s Captisol Technology Plays Key Role in the Manufacture of Gilead’s Veklury, the First FDA-Approved COVID-19 Treatment
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today highlighted the company’s role in the manufacturing of Veklury ® (remdesivir), Gilead Sciences’ antiviral drug for the treatment of patients with COVID-19 requiring hospitalization. Veklury is formulated with Ligand’s Captisol ® technology. Approved yesterday by the U.S. Food and Drug Administration, Veklury is the first and only approved COVID-19 treatment in the Un
HITGEN announces it has entered into a definitive agreement with Ligand Pharmaceuticals Inc. to acquire Vernalis Limited, Cambridge, UK-based world leaders in fragment and structure-based drug discovery research.
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the sale of Ligand’s Vernalis research operations and internal programs to HitGen Inc. (SHA: 688222) for $25 million in cash. Under the terms of the agreement, Ligand will retain economic rights on complet